Pfizer Inc. (NYSE:PFE) Shares Sold by Peddock Capital Advisors LLC

Peddock Capital Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,211 shares of the biopharmaceutical company’s stock after selling 3,430 shares during the period. Peddock Capital Advisors LLC’s holdings in Pfizer were worth $961,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. GHP Investment Advisors Inc. lifted its holdings in Pfizer by 5.2% in the second quarter. GHP Investment Advisors Inc. now owns 12,589 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 620 shares during the period. Parallel Advisors LLC lifted its stake in shares of Pfizer by 19.1% in the 2nd quarter. Parallel Advisors LLC now owns 108,180 shares of the biopharmaceutical company’s stock worth $3,027,000 after acquiring an additional 17,370 shares during the period. Thoroughbred Financial Services LLC boosted its holdings in shares of Pfizer by 102.9% in the second quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock valued at $900,000 after acquiring an additional 16,313 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Pfizer by 9.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 328,170 shares of the biopharmaceutical company’s stock valued at $9,182,000 after acquiring an additional 27,178 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock worth $287,077,000 after purchasing an additional 238,850 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Stock Up 0.3 %

NYSE:PFE traded up $0.07 during trading hours on Monday, hitting $26.79. 28,317,581 shares of the company’s stock traded hands, compared to its average volume of 34,470,996. The stock’s fifty day moving average price is $26.18 and its two-hundred day moving average price is $28.04. The firm has a market cap of $151.82 billion, a P/E ratio of 36.20, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) earnings per share. The firm’s revenue was up 31.2% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.42%. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is currently 232.43%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.